Chilton Capital Management LLC Purchases 1,598 Shares of Stryker Corporation (NYSE:SYK)

Chilton Capital Management LLC lifted its stake in Stryker Corporation (NYSE:SYK - Free Report) by 2.1% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 78,105 shares of the medical technology company's stock after purchasing an additional 1,598 shares during the period. Stryker accounts for 1.3% of Chilton Capital Management LLC's portfolio, making the stock its 26th largest position. Chilton Capital Management LLC's holdings in Stryker were worth $29,075,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently bought and sold shares of SYK. Brighton Jones LLC boosted its holdings in Stryker by 15.4% during the fourth quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company's stock worth $1,643,000 after buying an additional 609 shares during the last quarter. Assetmark Inc. grew its stake in shares of Stryker by 28.1% during the 4th quarter. Assetmark Inc. now owns 1,298 shares of the medical technology company's stock worth $467,000 after acquiring an additional 285 shares in the last quarter. Proficio Capital Partners LLC increased its stake in Stryker by 46.2% in the 4th quarter. Proficio Capital Partners LLC now owns 1,656 shares of the medical technology company's stock valued at $596,000 after buying an additional 523 shares during the last quarter. Vestmark Advisory Solutions Inc. boosted its position in Stryker by 9.1% during the fourth quarter. Vestmark Advisory Solutions Inc. now owns 1,819 shares of the medical technology company's stock valued at $655,000 after purchasing an additional 152 shares during the last quarter. Finally, E Fund Management Co. Ltd. boosted its holdings in shares of Stryker by 70.4% in the 4th quarter. E Fund Management Co. Ltd. now owns 1,704 shares of the medical technology company's stock valued at $614,000 after buying an additional 704 shares during the last quarter. Institutional investors own 77.09% of the company's stock.

Stryker Trading Down 0.7%

Shares of NYSE:SYK traded down $2.63 during mid-day trading on Monday, hitting $392.65. The company had a trading volume of 283,851 shares, compared to its average volume of 1,344,065. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.64 and a quick ratio of 1.00. The company has a market capitalization of $149.87 billion, a PE ratio of 53.08, a price-to-earnings-growth ratio of 2.98 and a beta of 0.91. The firm has a fifty day moving average price of $382.92 and a 200 day moving average price of $376.39. Stryker Corporation has a one year low of $314.93 and a one year high of $406.19.

Stryker (NYSE:SYK - Get Free Report) last issued its earnings results on Thursday, May 1st. The medical technology company reported $2.84 earnings per share for the quarter, topping analysts' consensus estimates of $2.73 by $0.11. The company had revenue of $5.87 billion for the quarter, compared to analyst estimates of $5.68 billion. Stryker had a return on equity of 23.74% and a net margin of 12.31%. Stryker's revenue for the quarter was up 11.9% on a year-over-year basis. During the same period in the prior year, the firm earned $2.50 earnings per share. As a group, research analysts forecast that Stryker Corporation will post 13.47 EPS for the current year.

Stryker Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, July 31st. Shareholders of record on Monday, June 30th will be issued a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a yield of 0.86%. The ex-dividend date is Monday, June 30th. Stryker's dividend payout ratio is 45.41%.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the company. BTIG Research set a $403.00 price objective on Stryker and gave the company a "buy" rating in a research note on Monday, April 14th. Roth Mkm raised their target price on shares of Stryker from $405.00 to $456.00 and gave the stock a "buy" rating in a report on Friday, May 2nd. Evercore ISI decreased their target price on shares of Stryker from $400.00 to $390.00 and set an "outperform" rating on the stock in a report on Friday, May 2nd. Truist Financial raised their price objective on Stryker from $390.00 to $400.00 and gave the company a "hold" rating in a research note on Monday, May 5th. Finally, JMP Securities reiterated a "market perform" rating on shares of Stryker in a research note on Monday, May 5th. Five research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $427.30.

Insider Buying and Selling

In other Stryker news, Director Ronda E. Stryker sold 200,000 shares of the business's stock in a transaction on Tuesday, May 6th. The stock was sold at an average price of $376.96, for a total value of $75,392,000.00. Following the transaction, the director owned 3,417,326 shares of the company's stock, valued at approximately $1,288,195,208.96. The trade was a 5.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 5.20% of the company's stock.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.